Compare Sunrun Inc (RUN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs TG Therapeutics Inc — how do they compare? Sunrun Inc trades at $8.78 (market cap $2.12B), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: TG Therapeutics Inc is far larger — about 3.9× Sunrun Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| RUN | TGTX | |
|---|---|---|
Market Cap | $2.12B | $8.36B |
Sector | Technology | Health |
52-Week High | $21.41 | $59.06 |
52-Week Low | $8.37 | $26.94 |
Enterprise Value | $16.64B | $8.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $9.22, up 3.71% in the last session, with a bearish technical outlook despite recent earnings beats. The stock shows low valuation multiples (P/E of 5.99, P/S of 0.69) and strong analyst support (62% buy ratings), but faces headwinds from negative operating cash flow and high debt. Recent news highlights guidance cuts and solar tariff impacts, while storage growth offers a potential catalyst.
The outlook is mixed: attractive valuations and storage partnerships support upside to the $14.70 consensus target, but profitability pressures and cash flow challenges pose risks. Investors should weigh low multiples against execution risks in a competitive solar market.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
